Detalles de la búsqueda
1.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644155
2.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644154
3.
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Gastroenterology
; 162(7): 1891-1910, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35227777
4.
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.
Am J Gastroenterol
; 113(6): 872-882, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29867173
5.
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
J Pediatr
; 201: 166-175.e3, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30054164
6.
Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease.
Clin Ther
; 46(1): 30-39, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37932155
7.
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
J Crohns Colitis
; 18(3): 416-423, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797293
8.
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
J Crohns Colitis
; 2023 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38069472
9.
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.
Adv Ther
; 40(5): 2311-2325, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36917429
10.
Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis.
United European Gastroenterol J
; 10(5): 485-495, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35560533
11.
Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection.
Clin Ther
; 43(3): 629-636, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549311
12.
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
J Crohns Colitis
; 15(12): 2001-2010, 2021 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34077509
13.
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.
Therap Adv Gastroenterol
; 13: 1756284820938960, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32733600
14.
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results.
Arthritis Care Res (Hoboken)
; 72(10): 1420-1430, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31421019
15.
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
Inflamm Bowel Dis
; 25(9): 1522-1531, 2019 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30753510
16.
Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis.
J Comp Eff Res
; 7(10): 959-974, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30129776
17.
Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate.
J Rheumatol
; 45(12): 1628-1635, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30173153
18.
Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial.
Rheumatol Ther
; 5(1): 123-134, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29574622
19.
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study.
Rheumatol Ther
; 4(1): 85-96, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28361468
20.
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.
RMD Open
; 3(2): e000465, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28955494